Does successful smoking cessation reduce anxious arousal among treatment-seeking smokers?

Samantha G. Farris a,∗, Nicholas P. Allan b, Patricia C. Morales c, Norman B. Schmidt b, Michael J. Zvolensky a,c

a University of Houston, Department of Psychology, 126 Fred J. Heyne Building, Suite 104, Houston, TX 77204, USA
b Florida State University, Department of Psychology, 1107 West Call Street, Tallahassee, FL 32306, USA
c The University of Texas MD Anderson Cancer Center, Department of Behavioral Science, 1155 Pressler Street, Houston, TX 77030, USA

ARTICLE INFO
Article history:
Received 11 March 2015
Received in revised form 3 June 2015
Accepted 29 July 2015
Available online 12 September 2015

Keywords:
Smoking cessation
Tobacco
Prevention
Hyperarousal

ABSTRACT

Introduction: There is limited work that has examined the effect of quitting smoking on anxious arousal, an underlying dimension of anxiety symptoms and psychopathology.

Method: Smokers (n = 185, 54.1% female) enrolled in a smoking cessation treatment trial were monitored post-cessation in terms of abstinence status (biochemically verified; at Weeks 1, 2, and Month 1 post-quit) and severity of panic-relevant symptoms (self-reported; at Month 1 and 3 post-quit). Structural equation models were conducted, adjusting for participant sex, age, treatment condition, and pre-cessation nicotine dependence, presence of depressive/anxiety disorders, anxious arousal, and anxiety sensitivity.

Results: After adjusting for covariates, participants who remained abstinent for one month (n = 80; 43.2%) relative to those who did not (n = 105; 56.8%) demonstrated significant reductions in anxious arousal at Month 1 (β = −.26, p < .04) and Month 3 post-quit (β = −.36, p < .006); abstinence status had a non-significant effect on anxious arousal severity at Month 3 after controlling for Month 1 anxious arousal (β = −.18, p > .05).

Discussion: Findings align with theoretical models of smoking-anxiety interplay and suggest that smoking cessation can result in reductions in anxious arousal.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Smokers with comorbid psychiatric disorders show less success in being able to quit smoking, which contribute to the stagnation of smoking cessation rates well-documented over recent years (Goodwin, Zvolensky, Keyes, & Hasin, 2012; Ziedonis et al., 2008). Anxiety symptoms and disorders, in particular, serve to maintain and even promote tobacco use and dependence (Morissette, Tull, Gulliver, Kamholz, & Zimmering, 2007) and impair quit success (Piper, Cook, Schlam, Jorenby, & Baker, 2011). Indeed, there are bidirectional associations between smoking and anxiety symptoms/disorders (Amering et al., 1999; Cosci, Knuts, Abrams, Griez, & Schruers, 2010; Zvolensky & Bernstein, 2005; Zvolensky, Feldner, Leen-Feldner, & McLeish, 2005). For example, the initiation of cigarette smoking typically precedes the initial onset of anxiety psychopathology (e.g., Bernstein, Zvolensky, Schmidt, & Sachs-Ericsson, 2007) and smoking increases the later risk for anxiety psychopathology (Breslau, Novak, & Kessler, 2004; I sensée, Wittchen, Stein, Hofler, & Lieb, 2003; Johnson et al., 2000; Jamal, Does, Penninx, & Cuijpers, 2011). Additionally, successful smoking cessation is associated with reductions in anxiety symptoms and decreased likelihood of anxiety disorders among those with pre-existing disorders (Cavazos-Rehg et al., 2014; McDermott, Marteau, Hollands, Hankins, & Aveyard, 2013; Shahab, Andrew, & West, 2014; Taylor et al., 2014).

Given the phenotypic heterogeneity in the expression of symptoms across anxiety disorders (Watson, 2005), transdiagnostic models of emotional disorders (anxiety and depressive conditions) have suggested underlying dimensional constructs may serve to explain between-individual variability in symptom presentation (i.e., tripartite model; Clark & Watson, 1991; Watson & Clark et al., 1995; Watson & Weber et al., 1995). Anxious arousal, reflecting the extent to which one experiences somatic arousal and tension (e.g., shortness of breath, dizziness, lightheadedness, trembling, shaking), is a core, cross-cutting feature of many anxiety disorders (Watson & Clark et al., 1995). Anxious arousal also is related to...
smoking (see review; Ameringer & Leventhal, 2010). For example, anxious arousal is associated with higher levels of nicotine dependence (Zvolensky, Stewart, Vujanovic, Gavric, & Steeves, 2009) and a history of a greater number of unsuccessful smoking cessation attempts (Zvolensky, Johnson, Leyer, Hogan, & Tursi, 2009). Further, poorer perceptions of physical health are associated with higher levels of anxious arousal among daily smokers (McLeish, Zvolensky, Bonn-Miller, & Bernstein, 2006). Evidence also suggests that smoking heaviness and anxious arousal may be bi­directionally linked by affects-regulatory smoking motives (Johnson, Stewart, Zvolensky, & Steeves, 2009). Moreover, anxious arousal is associated with experiencing greater increases in abstinence-induced depression and fatigue (Leventhal, Ameringer, Osborn, Zvolensky, & Langdon, 2013), which was not seen in other tripartite aspects of anxiety and depression (e.g., anhedonic depression). Yet, there is no empirical data on the nature of anxious arousal after a smoking cessation attempt. This gap in knowledge is clinically important to address in order to better understand anxiety phenomena broadly during the process of quitting, which may have cross-cutting implications across specific forms of anxiety psychopathology. That is, based on complex heterogeneity across and within different anxiety disorders, examining anxious arousal, a more parsimonious trans­diagnostic construct, would provide more precise and informative information regarding the patterning of (anxiety) symptoms after a quit attempt.

The majority of empirical evidence suggests that smoking cessation yields on reductions of anxiety symptoms (Becoña, Vázquez, & Míguez, 2002; Dawkins, Powell, Pickering, Powell, & West, 2009; McDermott et al., 2013; Solomon et al., 2006), although there is large heterogeneity across studies (see meta-analysis; Taylor et al., 2014). It is possible that variability in study findings is, in part, a function of motivation to quit smoking (Taylor et al., 2014), but also may be due to broad types of measurement of anxiety symp­toms utilized in existing studies that do not permit an examination of ‘pure’ anxious arousal (i.e., they cannot distinguish between anxiety symptoms that do and do not overlap with depression; Taylor et al., 2014). For this reason, it is important to examine the nature of anxious arousal as a function of smoking cessation. Reductions in anxious arousal after smoking cessation would be expected based on the understanding that nicotine has anxiogenic properties over time and can actually promote greater levels of anxiety over time (Kassel, Stroud, & Paronis, 2003; Leventhal & Zvolensky, 2015; Zvolensky & Bernstein, 2005), despite the (perceived or actual) affect regulation and modulation properties of smoking (nicotine) in the immediate context of use—likely due to narrowing of attentional focus to most immediate stimuli in envi­ronment and away from subjective distressing thoughts, feelings or sensations (Kassel & Unrod, 2000). Thus, although abstinence from smoking may induce symptoms in the short-term (Vessichio, Termine, & George, 2002; Zvolensky, Lejue, Kahler, & Brown, 2004), perhaps due to heightened cognitive–affective reactivity to interoceptive perturbation (Zvolensky & Bernstein, 2005), quitting smoking should theoretically lessen the severity of anxious arousal during periods of sustained abstinence. To address this question, the present study tested the hypothesis that abstainers, relative to non-abstainers, would report less severe anxious arousal at one- and three-months post cessation. These effects were expected to be significant after adjusting for participant gender, age, study treatment condition, and severity of pre-quit levels of nicotine dependence and anxious arousal. The effects were also expected to be significant after adjusting for the presence of depressive/anxiety disorders pre-cessation. Additionally, unlike past work (Taylor et al., 2014), to strengthen the test of these effects, pre­quit levels of anxiety sensitivity (i.e., tendency to misinterpret the meaning of anxious arousal or fear of anxious arousal) was adjusted for in analyses.

2. Material and methods

2.1. Participants

Participants (n = 185; 54.1% female; M_age = 39.41, SD = 13.76) were adult daily smokers recruited as part of a smoking ces­sation and panic disorder prevention trial (clinicaltrials.gov #NCT01753141). Eligibility criteria for the parent study included: smoking ≥8 cigarettes per day for at least the past year, and motivation to quit rated at least 5 or higher on a 10-point scale. Exclusionary criteria included current use of smoking cessation products or treatment, regular use of other tobacco products, unstable psychotropic medication (had to be stable ≥3 months), history of panic disorder (defined by the DSM-IV-TR), post-month suicid­ality, a history of psychotic/spectrum disorders, current pregnancy or nursing and inability to provide informed consent. Participants were included in the current study if smoking cessation data were available for at least two of three post-quit follow-up appointments (i.e., Week 1, Week 2, and/or Month 1).

The majority of participants identified race as white (85.4%) and completed at least some college (80.6%). The average daily smoking rate was of this sample was 16.8 (SD = 8.39) cigarettes per day and on average participants reported daily smoking for 21.0 years (SD = 13.86). Moderate levels of nicotine dependence were reported among the sample per the Fagerström for Nicotine Depend­ence (M = 5.1, SD = 2.27) and baseline expired carbon monoxide (CO) averaged 20.6 ppm (SD = 11.99). Current (past-month) Axis I primary diagnoses were as follows: depressive/mood disorder (7.0%), alcohol use disorder (3.8%), substance use disorder (2.7%), social anxiety disorder (9.2%), specific phobia (3.8%), obsessive­compulsive disorder (1.6%), posttraumatic stress disorder (2.2%), and generalized anxiety disorder (5.4%).

2.2. Procedure

Participants were recruited through community-based adver­tisements at two treatment sites (University of Vermont, Burlington VT and Florida State University, Tallahassee, FL). Potentially-eligible participants were scheduled for a baseline assessment during which participants were assessed using a structured clinical di­agnostic assessment, provided a CO analysis to verify smoking status and completed a computerized battery of self-report questionnaires. Eligible participants were randomly assigned to one of two smoking cessation treatment programs and scheduled for treatment initiation approximately 1–2 weeks after the baseline assessment. Smoking cessation treatment consisted of either (1) a standard smoking cessation program (Fiore et al., 2008), or (2) anxiety-focused smoking cessation treatment (Zvolensky, Yartz, Gregor, Gonzalez, & Bernstein, 2008), both included use of nicotine replacement therapy via the transdermal nicotine patch, which was initiated at treatment session four (quit day). Treatment consisted of four 60-min weekly individual sessions conducted by a trained doctoral-level graduate student. Quit day occurred during the last treatment session (Session 4). All treatment was supervised by study authors (MJZ and NBS) and checked for treatment fidelity by independent reviewers. Follow-up assessments occurred at Week 1, Week 2, Month 1, Month 3 post-quit attempt. All participants provided informed consent prior to participation and the study protocol was approved by the Institutional Review Board at both institutions, where the study was conducted.

2.3. Measures

2.3.1. Descriptive measures

The Smoking History Questionnaire (SHQ; Brown, Lejue, Kahler, & Strong, 2002) is a self-report questionnaire used to assess smok-
ing history (e.g., onset of regular daily smoking), pattern (e.g., number of cigarettes consumed per day), and quit history. In the present study, the SHQ was employed to describe the sample on smoking history and patterns of use (e.g., smoking rate, years as a regular smoker).

The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/NP; First, Spitzer, Gibbon, & Williams, 2007) was used to assess current (past-year) and lifetime Axis I psychological disorders. This non-patient version of the SCID is commonly used in research with community participants (First et al., 2007). Interviews were administered by doctoral level graduate students or highly trained post-baccalaureate clinical research assistants with diagnostic assessment experience; interviewers were supervised by independent doctoral-level psychologists. All random selection of 12.5% of SCID assessments were checked to ensure diagnostic accuracy (no discrepancies were noted; 100% agreement). The SCID-I/NP was used in the current study to describe psychopathology among the sample. Further, the presence of a primary depressive/mood or anxiety disorder was included as a covariate.

2.3.2. Anxious arousal

The Inventory of Depressive and Anxiety Symptoms (IDAS; Watson et al., 2007) is a 64-item self-report measure of symptoms of major depression and related anxiety disorders. This measure yields one broad scale and several symptom scales. Respondents are asked to rate the degree to which they have experienced symptoms in the past two weeks, scored on a 5-point Likert-type scale (1 = “not at all” to 5 = “extremely”). One scale from the IDAS includes items that reflect sympathetic arousal, which is often seen in panic attacks and panic disorder (thus is labeled the IDAS-Panic scale). This scale includes 8 items that were adapted from the Mood and Anxiety Symptom Questionnaire—Anxious Arousal Scale (MASQ; Watson & Clark, 1995), which includes items like “I was trembling or shaking”, “My heart was racing or pounding”, or “I was short of breath”. The IDAS-Panic subscale can be viewed as a short-form version of the MASQ-Anxious Arousal scale (Watson et al., 2007), thus was used in the current study as an index of the severity of anxious arousal at baseline, Month 1 and Month 3. Psychiatric populations have been found to average scores of 15.1 (SD = 6.10) on the IDAS-Panic scale (possible range = 8–40). This scale has strong psychometric properties, including test-retest reliability, internal consistency, and convergent validity with self-report measure of anxiety and diagnostic assessments of anxiety disorders (Watson et al., 2007).

2.3.3. Covariates

The Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerström, 1991) is a six-item scale designed to assess gradations in tobacco dependence. Scores range from 0 to 10, with higher scores reflecting higher levels of physiological dependence on nicotine. The FTND measure has shown adequate levels of internal consistency, positive relations with key smoking variables (e.g., saliva cotinine), and high test-retest reliability (Heatherton et al., 1991).

The Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) is an 18-item psychologically-sound self-report measure in which respondents indicate the extent to which they are concerned about possible negative consequences of anxiety-related symptoms (e.g., “It scares me when my heart beats rapidly”). Responses are rated on a 5-point Likert scale ranging from 0 (very little) to 4 (very much) and summed to generate a total score. The ASI-3 has strong and improved psychometric properties relative to previous measures of the construct (Taylor et al., 2007).

2.3.4. Biochemical verification of smoking

Carbon monoxide (CO) analysis of breath samples was used as a biochemical verification of smoking status. Expired air CO levels were assessed using a CMD/CO Carbon Monoxide Monitor (Model 3110; Spirometrics, Inc.). CO breath samples at each time point were used as an indicator of abstinence (expired CO ≤4 ppm, as abstinent; per Perkins, Karelitz, & Jao, 2013).

2.4. Definition of quit status

Quit status (i.e., smoking cessation following the intervention: categorized as 0 = non-quitters, 1 = successful quitters) was based on Week 1, Week 2, and Month 1 post-intervention biochemical verification via CO levels ≤4 ppm. To balance accurate classification with missing data in verification of quit status, it was determined that individuals would be included in the analyses if they had data available for at least two time points, and for whom a consistent pattern (i.e., non-quitter or successful quitter) was present. For example, if an individual had data available at Week 1 and at Month 1, but the data conflicted regarding quit status categorization, this individual was excluded from data analysis. However, if an individual had data available at Week 1 and at Month 1, and both time points were consistent regarding quit status, then this individual would be classified accordingly.

Compared to individuals with CO data at the Quit Week appointment (n = 254), 86.2% (n = 219) had CO data at Week 1, 81.1% (n = 206) had CO data at Week 2, and 71.3% (n = 181) had CO data at Month 1. Of the 254 individuals with CO data at Quit Week, 215 participants had CO data available for at least two of three time points. There were no differences in gender, treatment condition, presence of depressive/anxiety disorders, or baseline FTND scores between individuals with and without CO data available at two or more post-intervention appointments. Baseline ASI-3 scores were significantly different (F[1,252] = 5.55, p = .02) such that individuals who had CO data available at two or more post-intervention appointments had significantly lower baseline ASI-3 scores (M = 13.8, SD = 11.56) than individuals who did not have data present at two or more post-intervention time points (M = 18.7, SD = 13.61). In addition, baseline levels of anxious arousal were significantly different (F[1,252] = 5.95, p = .02), such that individuals who had CO data available had lower IDAS-Panic scores (M = 10.5, SD = 3.28) than did individuals who did not have CO data available (M = 12.1, SD = 5.42). Finally, age was also significantly different (F[1,252] = 12.96, p < .001) such that individuals who had CO data available at two or more post-intervention appointments were significantly older (Mage = 39.5 years, SD = 13.75) than individuals who did not have data present at two or more post-intervention time points (Mage = 31.0, SD = 13.11). Of the 215 participants with CO data available for at least two time points, 80 (37.2%) were classified as smoking, 105 (48.8%) were classified as abstinent, and 30 (14.0%) were unable to be classified because no consistent pattern for quit status was detected. There were no differences in gender, age, treatment condition, or baseline nicotine dependence, panic symptoms, or anxiety sensitivity between individuals included in the analyses and those excluded because of inconsistent quit status.

2.5. Data analytic plan

To examine the effects of quit status on anxious arousal, structural equation modeling (SEM) was conducted in Mplus version 7.1 (Muthén & Muthén, 2012). IDAS-Panic items at baseline, Month 1, and Month 3 were modeled as categorical indicators of anxious arousal factors using the robust weighted least squares estimator (WLSMV in Mplus). Overall model fit was assessed using the χ² statistic and several fit indices, including the comparative fit index (CFI) and the root mean square error of approximation
(RMSEA), with accompanying 90% confidence intervals (CIs). A non-significant $\chi^2$ test statistic indicates good model fit; however, this statistic can be too restrictive, especially when numerous items are used per factor (Hu & Bentler, 1999; Moshagen, 2012; Mulaik, 2007). CFI values greater than .95 and RMSEA values less than .06 indicate good fit. CFI values greater than .90 and RMSEA values less than .08 indicate adequate fit. Finally, lower bound 90% CIs less than .05 indicate that good model fit cannot be ruled out whereas upper bound 90% CIs greater than .10 indicate that poor model fit cannot be ruled out (Brown, 2006; Browne & Cudeck, 1992).

A baseline measurement model of Baseline, Month 1, and Month 3 anxious arousal factors with correlations between all factors was first fit to the data. Following this, an SEM model with directionality of effects, quit status, and covariates (e.g., gender, age, treatment condition, and baseline ASI-3 and FTND scores, and presence of depressive/ anxiety disorders) predicting anxious arousal factors at Month 1 and Month 3, was fit to the data (Fig. 1).

### 3. Results

#### 3.1. Descriptive statistics and correlations

Based on quit status, 185 individuals could be classified in the current study and were either classified as non-quitters ($n = 80$) or as successful quitters ($n = 105$). Differences between non-quitters and successful quitters on baseline demographic variables, rates of depressive mood and anxiety disorders, smoking status, anxiety sensitivity, and nicotine dependence are provided in Table 1. Correlations (Pearsons for continuous-by-continuous variables, point-biserial for categorical-by-continuous, and phi coefficients for categorical-by-categorical) and means are provided by quit status for all variables in Table 2.

#### 3.2. Structural equation model examining the effects of quit status on anxious arousal

A confirmatory factor analysis (CFA) of Baseline, Month 1, and Month 3 anxious arousal factors provided adequate fit to the data ($\chi^2 = 485.42$, $p < .05$, $CFI = .92$, RMSEA = .07, 90% CI [.06, .08]). A model including directionality of anxious arousal factors (i.e., Baseline anxious arousal predicting Month 1 and Month 3 anxious arousal and Month 1 anxious arousal predicting Month 3 anxious arousal); quit status and the covariates, including, gender, age, baseline anxiety sensitivity and nicotine dependence, mood/anxiety disorder diagnosis, and treatment condition provided adequate fit to the data ($\chi^2 = 582.77$, $p < .05$, CFI = .93, RMSEA = .05, 90% CI [.04, .06]). Controlling for the baseline anxious arousal factor and covariates, quit status significantly predicted anxious arousal at Month 1 ($\beta = -.23$, $p = .04$), indicating that individuals who successfully achieved abstinence showed a .23 SD reduction in anxious arousal at Month 1 as compared to individuals who did not achieve abstinence. Controlling for the Baseline and Month 1 anxious arousal factors as well as covariates, quit status was non-significantly associated with anxious arousal at Month 3 ($\beta = -.18$, $p = .09$).

To determine if the effects of quit status was as directly predictor of Month 3 anxious arousal, the effect of quit status on anxious arousal at Month 3 was examined controlling for anxious arousal at baseline only (see Fig. 2). This model provided adequate fit to the data ($\chi^2 = 332.06$, $p < .05$, $CFI = .92$, RMSEA = .06, 90% CI [.04, .07]). As expected, after controlling for baseline anxious arousal and covariates, quit status significantly predictive anxious arousal at Month 3 ($\beta = -.36$, $p = .006$), indicating that individual who successfully quit

### Table 1

Comparison of demographics, mood and anxiety disorder status, baseline anxiety sensitivity, nicotine dependence, and anxious arousal between cigarette non-quitters and quitters.

<table>
<thead>
<tr>
<th></th>
<th>Non-quitters ($n = 80$)</th>
<th>% Quitters ($n = 105$)</th>
<th>$\chi^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (% male)</td>
<td>50.0</td>
<td>42.9</td>
<td>.93</td>
</tr>
<tr>
<td>ASI-3 Diagnoses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>32.5</td>
<td>26.7</td>
<td>.75</td>
</tr>
<tr>
<td>Sad</td>
<td>7.5</td>
<td>10.5</td>
<td>.48</td>
</tr>
<tr>
<td>Specific phobia</td>
<td>7.5</td>
<td>1.0</td>
<td>5.35</td>
</tr>
<tr>
<td>OCD</td>
<td>1.3</td>
<td>1.9</td>
<td>.12</td>
</tr>
<tr>
<td>PTSD</td>
<td>2.5</td>
<td>1.9</td>
<td>.08</td>
</tr>
<tr>
<td>GAD</td>
<td>8.8</td>
<td>2.9</td>
<td>3.08</td>
</tr>
<tr>
<td>Mean</td>
<td>38.6</td>
<td>14.06</td>
<td>13.57</td>
</tr>
<tr>
<td>SD</td>
<td>4.00</td>
<td>5.20</td>
<td>.47</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTND</td>
<td>5.3</td>
<td>2.21</td>
<td>.56</td>
</tr>
<tr>
<td>ASI-3</td>
<td>14.9</td>
<td>11.35</td>
<td>.92</td>
</tr>
<tr>
<td>IDAS panic</td>
<td>10.7</td>
<td>2.70</td>
<td>.380</td>
</tr>
</tbody>
</table>

Note: SAD = social anxiety disorder. OCD = obsessive-compulsive disorder. PTSD = posttraumatic stress disorder. GAD = generalized anxiety disorder. FTND = Fagerström Test for Nicotine Dependence. ASI-3 = Anxiety Sensitivity Index-3. $SD =$ standard deviation.

$p < .05.$
smoking showing a .36 SD reduction in anxious arousal at Month 3 as compared to individual who did not quit smoking.

4. Discussion

The current study examined the impact of biochemically verified continued smoking abstinence (for one month), relative to non-abstinence, in terms of its effect on anxious arousal at one- and three-months post-intervention, among a sample of treatment-seeking smokers. Of those included in analyses, approximately 43% of participants achieved biochemically-verified sustained abstinence for one-month post-quit attempt, whereas approximately 57% did not. As expected, after accounting for baseline level of anxious arousal, abstinence, relative to non-abstainers, evidenced statistically significant reductions in anxious arousal at Month 1 and Month 3 post-cessation; the effects were similar magnitude in size. After accounting for Month 1 reductions anxious arousal, the effect of abstinence status on Month 3 anxious arousal was non-significant, suggesting that the effect of abstinence status on Month 3 anxious arousal occurs through Month 1 reductions in anxious arousal. This set of findings compliments and uniquely extends existing work documenting the role of smoking cessation in terms of reduction of anxiety symptoms (Taylor et al., 2014). Indeed, relative to past work, the current findings are bolstered by the biochemical verification of smoking abstinence (across multiple time-points) and use of a conservative cut-point for defining abstinence (Perkins et al., 2013). These effects were apparent after accounting for the (non-significant) effects of gender, age, baseline levels of anxiety sensitivity and nicotine dependence, presence of depressive/anxiety disorders, and treatment condition.

It is also worth noting that the group of smokers who did not achieve abstinence did not demonstrate statistically significant decreases or increases in anxious arousal during follow-up assessments. Moreover, the current sample did not present with current/past panic psychopathology (panic attacks, panic disorder, agoraphobia) due to the nature of the parent study. Thus, even among smokers without panic-spectrum psychopathology who may have had other emotional disorders where anxious arousal may be relevant, sustained smoking is related to reductions in anxious arousal. These data therefore provide compelling evidence that (successful) smoking cessation contributes to reductions in anxious arousal over time. Future work may benefit by examining the sub-set of smokers who struggled to maintain smoking abstinence (those who demonstrated a relapsing-remitting pattern of smoking). It has been proposed that those smokers who may continue to persist in attempting to quit (the ‘struggling quitter’) may be more prone to experience increases in smoking-relevant symptoms (e.g., protracted withdrawal, craving) and subsequent increases in depressive symptoms during early quit phases (Berlin, Chen, & Covey, 2010) although this not consistently documented (Capron, Allan, Norr, Zvolensky, & Schmidt, 2014). To the best of our knowledge, no work has addressed this type of prediction in relation to anxious arousal (or anxiety symptoms).

There are a number of study limitations. First, quit status abstinence was assessed by three expired CO measurements collected during the four weeks following the quit attempt. Although biochemical verification of smoking status is superior to self-reported abstinence, expired CO measurement is sensitive to recency of smoking. Thus, it is possible that a smoker may have engaged in between-assessment smoking, but achieved smoking abstinence.


Adolescents in the current sample reported a greater number of depressive symptoms compared to the adult sample. Furthermore, this group of adolescents reported greater levels of depressive symptoms compared to the adult sample.